Q4 2025 Ginkgo Bioworks Holdings Inc Earnings Call Transcript
Key Points
- Ginkgo Bioworks Holdings Inc (DNA) is focusing on autonomous labs, which are expected to transform biotechnology by integrating robotics and AI.
- The company plans to divest its biosecurity business to focus investments on autonomous labs, allowing for more targeted growth.
- Ginkgo Bioworks Holdings Inc (DNA) has significantly reduced its cash burn by 55% in 2025, setting a strong financial foundation for future investments.
- The company secured a $47 million deal with Pacific Northwest National Labs, showcasing interest from federal entities in autonomous labs.
- Ginkgo Bioworks Holdings Inc (DNA) is expanding its autonomous lab capacity in Boston, aiming to demonstrate the viability of replacing traditional labs with automated systems.
- Cell engineering revenue decreased by 26% in Q4 2025 compared to Q4 2024, indicating challenges in maintaining growth in this segment.
- The company is not providing revenue guidance for 2026, focusing instead on cash burn, which may concern investors looking for revenue growth indicators.
- Ginkgo Bioworks Holdings Inc (DNA) is undergoing restructuring, which has led to a decrease in the number of revenue-generating programs.
- The biosecurity business, despite being a decent-sized operation, is being spun off, which could lead to a loss of revenue from this segment.
- Adjusted EBITDA decreased from $57 million in Q4 2024 to $36 million in Q4 2025, reflecting the impact of restructuring and reduced revenues.
These risks and uncertainties, including our most recent 10-K. Today, in addition to updating you on the quarter results, we're going to provide insight into the autonomous lab, how we believe it will transform biotechnology, and how we plan to commercialize autonomous labs going forward.
As usual, we'll end with a Q&A session and I'll take questions from analysts, investors, and the public. You can submit those questions to us in advance via X, #ginkgoresults, or through email, investors@ginkgo bioworks.com. All right, over to you, Jason.
All right, thanks, Daniel. So Q4, was really a breakout quarter for us, in sort of defining and really leading in the category of autonomous labs. And so you're going to hear a lot from me about that in the future, but, I want to start by saying our mission remains to make biology easier to engineer. But in 2026, the techno
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
